AA
ORKA

AlphaCentric Advisors’s Oruka Therapeutics ORKA Stock Holding History

AlphaCentric Advisors’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$622K Sell
6,531
-4,975
-43% -$331K 0.53% 66
2026
Q1 		$564K Buy
11,506
+626
+6% +$21.8K 0.56% 52
2025
Q4 		$330K Buy
+10,880
New +$303K 0.33% 100
2024
Q4 		$119K Buy
+6,140
New +$150K 0.12% 151

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

AlphaCentric Advisors's ORKA Position: Q2 2026 in Review

AlphaCentric Advisors reduced its Oruka Therapeutics (ORKA) stake by 43% in Q2 2026, selling an estimated $331K and leaving 6,531 shares worth $622K. The position accounts for 0.53% of the portfolio, ranked #66.

AlphaCentric Advisors first reported a position in ORKA in Q4 2024 and has held it in 4 quarters since. 256 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • AlphaCentric Advisors held 6,531 shares of Oruka Therapeutics worth $622K as of Q2 2026.
  • AlphaCentric Advisors sold 4,975 Oruka Therapeutics shares in Q2 2026, an estimated $331K.
  • Oruka Therapeutics made up 0.53% of AlphaCentric Advisors's portfolio in Q2 2026, its #66 holding.
  • AlphaCentric Advisors first reported a position in Oruka Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • 256 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.